抑郁障碍是最常见的精神障碍之一,严重影响患者的生活、工作及社会功能。抑郁障碍患者往往伴有不同程度的认知功能损害,如记忆力下降、注意力集中困难等,给患者的日常生活和社会适应能力带来巨大挑战。临床上,多采用无抽搐电痉挛治疗(el...抑郁障碍是最常见的精神障碍之一,严重影响患者的生活、工作及社会功能。抑郁障碍患者往往伴有不同程度的认知功能损害,如记忆力下降、注意力集中困难等,给患者的日常生活和社会适应能力带来巨大挑战。临床上,多采用无抽搐电痉挛治疗(electroconvulsive therapy without convulsions, MECT)和SSRIs类药物治疗抑郁障碍。这些治疗方法不仅能有效改善抑郁症状,也在一定程度上改善患者的认知功能障碍,进而促进患者社会功能的恢复。本文就MECT及SSRIs类药物治疗对抑郁障碍患者认知功能影响予以综述。Depression disorder is one of the most common mental disorders, which seriously affects the life, work and social function of patients. Patients with depressive disorders are often accompanied by varying degrees of cognitive impairment, such as memory decline, difficulty concentrating attention, etc., which brings great challenges to patients’ daily lives and social adaptability. Clinically, electroconvulsive therapy without convulsions (MECT) and SSRIs are commonly used to treat depressive disorders. These treatment methods can not only effectively improve the symptoms of depression but also improve the cognitive dysfunction of patients to a certain extent, and then promote the recovery of patients’ social function. This article reviews the effects of MECT and SSRIs on cognitive function in patients with depressive disorder.展开更多
精神分裂症作为21世纪精神卫生工作的重点,同时作为临床上常见的较为严重的精神障碍之一,一直是临床重点管理及防控的工作内容。精神分裂症的治疗也作为各项研究关注的重点。神经递质以及脑源性神经营养因子的异常作为精神分裂症发病机...精神分裂症作为21世纪精神卫生工作的重点,同时作为临床上常见的较为严重的精神障碍之一,一直是临床重点管理及防控的工作内容。精神分裂症的治疗也作为各项研究关注的重点。神经递质以及脑源性神经营养因子的异常作为精神分裂症发病机制中重要环节也常被人关注。本文综述了无抽搐电休克(modified electroconvulsive therapy, MECT)联合二代抗精神病药物治疗精神分裂症的疗效及其对神经递质、脑源性神经营养因子(BDNF)的影响等,从多个方面探讨并总结目前精神分裂症治疗的进展。As the focus of mental health work in the 21st century, and as one of the more serious mental disorders commonly seen in clinical practice, schizophrenia has always been the focus of clinical management, prevention and control. The treatment of schizophrenia has also been the focus of various studies. Abnormalities in neurotransmitters and brain-derived neurotrophic factors are also often considered an important part of the pathogenesis of schizophrenia. This article reviews the efficacy of modified electroconvulsive therapy (MECT) combined with second-generation antipsychotic drugs in the treatment of schizophrenia and its effects on neurotransmitters and brain-derived neurotrophic factor (BDNF). It explores and summarizes the current progress in the treatment of schizophrenia from multiple perspectives.展开更多
文摘抑郁障碍是最常见的精神障碍之一,严重影响患者的生活、工作及社会功能。抑郁障碍患者往往伴有不同程度的认知功能损害,如记忆力下降、注意力集中困难等,给患者的日常生活和社会适应能力带来巨大挑战。临床上,多采用无抽搐电痉挛治疗(electroconvulsive therapy without convulsions, MECT)和SSRIs类药物治疗抑郁障碍。这些治疗方法不仅能有效改善抑郁症状,也在一定程度上改善患者的认知功能障碍,进而促进患者社会功能的恢复。本文就MECT及SSRIs类药物治疗对抑郁障碍患者认知功能影响予以综述。Depression disorder is one of the most common mental disorders, which seriously affects the life, work and social function of patients. Patients with depressive disorders are often accompanied by varying degrees of cognitive impairment, such as memory decline, difficulty concentrating attention, etc., which brings great challenges to patients’ daily lives and social adaptability. Clinically, electroconvulsive therapy without convulsions (MECT) and SSRIs are commonly used to treat depressive disorders. These treatment methods can not only effectively improve the symptoms of depression but also improve the cognitive dysfunction of patients to a certain extent, and then promote the recovery of patients’ social function. This article reviews the effects of MECT and SSRIs on cognitive function in patients with depressive disorder.
文摘精神分裂症作为21世纪精神卫生工作的重点,同时作为临床上常见的较为严重的精神障碍之一,一直是临床重点管理及防控的工作内容。精神分裂症的治疗也作为各项研究关注的重点。神经递质以及脑源性神经营养因子的异常作为精神分裂症发病机制中重要环节也常被人关注。本文综述了无抽搐电休克(modified electroconvulsive therapy, MECT)联合二代抗精神病药物治疗精神分裂症的疗效及其对神经递质、脑源性神经营养因子(BDNF)的影响等,从多个方面探讨并总结目前精神分裂症治疗的进展。As the focus of mental health work in the 21st century, and as one of the more serious mental disorders commonly seen in clinical practice, schizophrenia has always been the focus of clinical management, prevention and control. The treatment of schizophrenia has also been the focus of various studies. Abnormalities in neurotransmitters and brain-derived neurotrophic factors are also often considered an important part of the pathogenesis of schizophrenia. This article reviews the efficacy of modified electroconvulsive therapy (MECT) combined with second-generation antipsychotic drugs in the treatment of schizophrenia and its effects on neurotransmitters and brain-derived neurotrophic factor (BDNF). It explores and summarizes the current progress in the treatment of schizophrenia from multiple perspectives.
